SCHEMBL22826607

SCHEMBL22826607

O=c1c(CC(F)(F)F)nc2c(Cc3ccccc3)[nH]c(-c3ccccc3)cn1-2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 1/20 0.34
▸ LTB4R Q15722 1/20 0.34
▸ PSD A5PKW4 2/20 0.33
▸ ADORA3 P0DMS8 2/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ RAB9A P51151 3/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ GAA P10253 3/20 0.32
▸ HPGD P15428 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ HTT P42858 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ PDE2A O00408 1/20 0.32
▸ ALKBH3 Q96Q83 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2680267 0.89 ALDH1A1 (0.34) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL492636 0.88 LTB4R (0.41) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL19206667 0.85 LTB4R (0.39) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL2680919 0.85 ADORA3 (0.38) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL19206655 0.84 SMN1; SMN2 (0.34) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL16154083 0.84 ADORA3 (0.38) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL19206699 0.84 LTB4R (0.42) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL19206688 0.84 TACR1 (0.36) CDC7LTB4RPSDADORA3MAPT
SCHEMBL954143 0.83 LTB4R (0.43) CDC7LTB4RPSDADORA3ALDH1A1
SCHEMBL19206652 0.83 CDC7 (0.45) CDC7LTB4RPSDADORA3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661623-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use PROMEGA CORPORATION (US) 2023-05-30 — — US disclosed
US-11661623-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use PROMEGA CORPORATION (US) 2023-05-30 — — US disclosed
US-20200399676-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORPORATION 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661623-B2 Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use RNGTT, UPF1, LUC7L2 CDC7 1373/4885LTB4R 4291/4885PSD 2900/4885
US-20200399676-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE RNGTT, UPF1, LUC7L2 CDC7 1373/4885LTB4R 4291/4885PSD 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback